CARMAT announces the publication of an article on the Aeson’s autoregulation system in the ASAIO Journal

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the publication of an articleon the Aeson’s autoregulation system in the October 2021 issue of the ASAIO Journal, a peer reviewed publication of the American Society for Artificial Internal Organs.

The publication entitled“First Clinical Experience With the Pressure Sensor–Based Autoregulation of Blood Flow in an Artificial Heart” details the reliability and efficacy of the Aeson’s autoregulation control mechanism (auto-mode), designed to mimic normal physiologic responses to changing patient needs. Hemodynamic data from a cohort of 10 patients implanted with the deviceduring the European PIVOTAL study, recorded over 1,842 support days in auto-mode, were analyzed with respect to daily changing physiologic needs.The device was successfully switchedfrom manual mode to auto-mode in the operating room, following weaning from cardiopulmonary bypass (CPB), in all patients.